Ipsen has gained exclusive worldwide development and commercial rights to mesdopetam, a novel dopamine D3-receptor antagonist, from IRLAB.
Mesdopetam is being assessed in Phase IIb clinical trials as a potential treatment option for people living with Parkinson’s disease (PD) experiencing levodopa-induced dyskinesia (LID).
Mesdopetam has also shown antipsychotic properties in preclinical studies.
“By working in partnership, we aim to bring investigational mesdopetam to people living with Parkinson’s disease experiencing levodopa-induced dyskinesia,” said Dr Howard Mayer, Executive Vice President and Head of Research and Development at Ipsen.
“We are delighted to strengthen our pipeline and deepen our commitment to the neuroscience community around the world, including to patients living with this debilitating neurodegenerative disorder.”
Under the terms of the agreement, IRLAB will be eligible to receive up to $363 million, including an upfront cash payment of $28 million and up to $335 million in development, regulatory and commercial milestones.
IRLAB is also eligible to receive tiered low double-digit royalties on worldwide net sales of mesdopetam.